Lista de obras - Antonio M Grimaldi - Dominio Público Uruguay

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

scientific article published on 06 January 2021

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy

artículo científico publicado en 2017

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

artículo científico publicado en 2014

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

artículo científico publicado en 2015

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

artículo científico publicado en 2013

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series.

artículo científico publicado en 2015

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care

artículo científico publicado en 2017

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters.

artículo científico publicado en 2014

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

artículo científico publicado en 2016

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

artículo científico publicado en 2015

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients.

artículo científico publicado en 2015

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

artículo científico publicado en 2017

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

Do BRAF inhibitors select for populations with different disease progression kinetics?

artículo científico publicado en 2013

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

artículo científico publicado en 2013

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

artículo científico publicado en 2014

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg.

artículo científico publicado en 2014

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis.

artículo científico publicado en 2017

Electrochemotherapy in melanoma patients: a single institution experience

artículo científico publicado en 2015

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

scholarly article published in Cancer Immunology, Immunotherapy

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

artículo científico publicado en 2013

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

artículo científico publicado en 2012

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

artículo científico publicado en 2014

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

artículo científico publicado en 2016

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

article

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

artículo científico publicado en 2018

Lean oncology: a new model for oncologists

artículo científico publicado en 2012

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma ⬇️

artículo científico publicado en 2016

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab

artículo científico publicado en 2018

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

artículo científico publicado en 2013

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

artículo científico publicado en 2012

Serious haematological toxicity during and after ipilimumab treatment: a case series.

artículo científico publicado en 2014

Single versus combination immunotherapy drug treatment in melanoma

artículo científico publicado en 2015

Sunitinib: bridging present and future cancer treatment.

artículo científico publicado en 2007

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg

artículo científico publicado en 2013

The role of BRAF V600 mutation in melanoma

artículo científico publicado en 2012

Update on PEG-interferon α-2b as adjuvant therapy in melanoma

artículo científico publicado el 1 de septiembre de 2012

Vemurafenib beyond progression in a patient with metastatic melanoma: a case report

artículo científico publicado en 2015

Lista de obras de Antonio M Grimaldi

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series.

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters.

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients.

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

Do BRAF inhibitors select for populations with different disease progression kinetics?

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg.

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis.

Electrochemotherapy in melanoma patients: a single institution experience

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Lean oncology: a new model for oncologists

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma ⬇️

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

Serious haematological toxicity during and after ipilimumab treatment: a case series.

Single versus combination immunotherapy drug treatment in melanoma

Sunitinib: bridging present and future cancer treatment.

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg

The role of BRAF V600 mutation in melanoma

Update on PEG-interferon α-2b as adjuvant therapy in melanoma

Vemurafenib beyond progression in a patient with metastatic melanoma: a case report